Latus Bio: $97 Million Series A Raised To Advance Gene Therapy Platform Into Larger Patient Populations
By Amit Chowdhry ● Today at 7:17 AM
Latus Bio, a biotechnology company engineering scalable gene therapies for broader patient populations, has closed a $97 million Series A financing, including a $43 million extension led by 8VC, with participation from existing investors DCVC Bio, BioAdvance, Benjamin Franklin Technology Partners, Modi Ventures, Gaingels, and Hatch BioFund, along with new investors Korea Development Bank and Helen's Pink Sky Foundation.